ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $25.00 Price Target at JPMorgan Chase & Co.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price objective trimmed by JPMorgan Chase & Co. from $29.00 to $25.00 in a research report report published on Monday, Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock. A number of other analysts also recently issued reports on the stock. JMP […]

Related Keywords

United States ,Stifel Nicolaus ,Stephen Davis ,Pharmaceuticals Stock Performance ,Pharmaceuticals Daily ,Morgan Stanley ,Charles Schwab Investment Management Inc ,Qube Research Technologies Ltd ,Jpmorgan Chase Co ,Acadia Pharmaceuticals ,Sg Americas Securities ,Pharmaceuticals Inc ,Northern Trust Corp ,Free Report ,Moderate Buy ,Get Free Report ,Technologies Ltd ,Schwab Investment Management ,Trust Corp ,Nasdaq Acad ,Facad ,Medical ,Lower Price Target ,